Disease progression and treatment response of idiopathic epilepsy in Australian shepherd dogs

Journal of Veterinary Internal Medicine

Volumn 26, Issue 1, 2012, Pages 116-125

  Weissl, J ^a   Hulsmeyer V ^a   Brauer, C ^b   Tipold, A ^b   Koskinen, L L ^c   Kyostila K ^c   Lohi, H ^c   Sauter Louis, C ^a   Wolf, M ^a   Fischer, A ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

ABCB1(MDR1); Canine; Pharmacoresistance; Seizure

Indexed keywords

ANTICONVULSIVE AGENT; DNA; GLYCOPROTEIN P; PHENOBARBITAL;

ANIMAL; ANIMAL DISEASE; ARTICLE; CHEMISTRY; CLINICAL TRIAL; COHORT ANALYSIS; DOG; DOG DISEASE; EPILEPSY; FEMALE; GENETICS; GENOTYPE; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MALE; MULTICENTER STUDY; PATHOLOGY; PEDIGREE; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODEL; SEIZURE;

ANIMALS; ANTICONVULSANTS; COHORT STUDIES; DNA; DOG DISEASES; DOGS; EPILEPSY; FEMALE; GENOTYPE; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; P-GLYCOPROTEIN; PEDIGREE; PHENOBARBITAL; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODELS; SEIZURES;

ANIMALIA; CANIS FAMILIARIS;

EID: 84855746234     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2011.00853.x     Document Type: Article

References (49)

1. Srenk P, Jaggy A, Gaillard C, et al. Genetic basis of idiopathic epilepsy in the Golden Retriever. Tierärztl Prax 1994; 22:574-578.
2. Heynold Y, Faissler D, Steffen F, et al. Clinical, epidemiological and treatment results of idiopathic epilepsy in 54 Labrador Retrievers: A long-term study. J Small Anim Pract 1997;38:7-14.
3. Kathmann I, Jaggy A, Busato A, et al. Clinical and genetic investigations of idiopathic epilepsy in the Bernese Mountain Dog. J Small Anim Pract 1999;40:319-325.
4. Morita T, Shimada A, Takeuchi T, et al. Cliniconeuropathologic findings of familial frontal lobe epilepsy in Shetland Sheepdogs. Can J Vet Res 2002;66:35-41.
5. Patterson EE, Armstrong PJ, O'Brien DP, et al. Clinical description and mode of inheritance of idiopathic epilepsy in English Springer Spaniels. J Am Vet Med Assoc 2005;226:54-58.
6. Berendt M, Gullov CH, Christensen SL, et al. Prevalence and characteristics of epilepsy in the Belgian Shepherd variants Groenendael and Tervueren born in Denmark 1995-2004. Acta Vet Scand 2008;50:51.
7. Hülsmeyer V, Zimmermann R, Brauer C, et al. Epilepsy in Border Collies: Clinical manifestation, outcome, and mode of inheritance. J Vet Intern Med 2010;24:171-178.
8. Licht BG, Lin S, Luo Y, et al. Clinical characteristics and mode of inheritance of familial focal seizures in Standard Poodles. J Am Vet Med Assoc 2007;231:1520-1528.
9. Lohi H, Young EJ, Fitzmaurice SN, et al. Expanded repeat in canine epilepsy. Science 2005;307:81.
10. Oberbauer AM, Belanger JM, Grossman DI, et al. Genome-wide linkage scan for loci associated with epilepsy in Belgian Shepherd dogs. BMC Genet 2010;11:35.
11. Ekenstedt KJ, Patterson EE, Minor KM, et al. Candidate genes for idiopathic epilepsy in four dog breeds. BMC Genet 2011;12:38.
12. Martinez M, Modric S, Sharkey M, et al. The pharmacogenomics of P-glycoprotein and its role in veterinary medicine. J Vet Pharmacol Ther 2008;31:285-300.
13. Kennerly EM, Idaghdour Y, Olby NJ, et al. Pharmacogenetic association study of 30 genes with phenobarbital drug response in epileptic dogs. Pharmacogenet Genomics 2009;19:911-922.
14. Rogawski MA, Johnson MR. Intrinsic severity as a determinant of antiepileptic drug refractoriness. Epilepsy Curr 2008;8:127-130.
15. Potschka H. Transporter hypothesis of drug-resistant epilepsy: challenges for pharmacogenetic approaches. Pharmacogenomics 2010;11:1427-1438.
16. Lane SB, Bunch SE. Medical management of recurrent seizures in dogs and cats. J Vet Intern Med 1990;4:26-39.
17. Thomas WB. Seizures and narcolepsy. In: Dewey CW, ed. A Practical Guide to Canine and Feline Neurology. Ames, IA: Iowa State Press; 2008:193-212.
18. Pekcec A, Unkruer B, Stein V, et al. Over-expression of P-glycoprotein in the canine brain following spontaneous status epilepticus. Epilepsy Res 2009;83:144-151.
19. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;51:676-685.
20. Zimmermann R, Hulsmeyer VI, Sauter-Louis C, et al. Status epilepticus and epileptic seizures in dogs. J Vet Intern Med 2009;23:970-976.
21. Meierkord H, Boon P, Engelsen B, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol 2010;17:348-355.
22. Platt SR, Haag M. Canine status epilepticus: A retrospective study of 50 cases. J Small Anim Pract 2002;43:151-153.
23. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51:1069-1077.
24. Trepanier LA, Van Schoick A, Schwark WS, et al. Therapeutic serum drug concentrations in epileptic dogs treated with potassium bromide alone or in combination with other anticonvulsants: 122 cases (1992-1996). J Am Vet Med Assoc 1998;213:1449-1453.
25. Levitski RE, Trepanier LA. Effect of timing of blood collection on serum phenobarbital concentrations in dogs with epilepsy. J Am Vet Med Assoc 2000;217:200-204.
26. Monteiro R, Anderson TJ, Innocent G, et al. Variations in serum concentration of phenobarbitone in dogs receiving regular twice daily doses in relation to the times of administration. Vet Rec 2009;165:556-558.
27. Platt SR, Adams V, Garosi LS, et al. Treatment with gabapentin of 11 dogs with refractory idiopathic epilepsy. Vet Rec 2006;159:881-884.
28. Volk HA, Matiasek LA, Lujan Feliu-Pascual A, et al. The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs. Vet J 2008;176:310-319.
29. Hugnet C, Bentjen SA, Mealey KL. Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of Collies from France. J Vet Pharmacol Ther 2004;27:227-229.
30. Patterson EE, Mickelson JR, Da Y, et al. Clinical characteristics and inheritance of idiopathic epilepsy in Vizslas. J Vet Intern Med 2003;17:319-325.
31. Jokinen TS, Metsahonkala L, Bergamasco L, et al. Benign familial juvenile epilepsy in Lagotto Romagnolo dogs. J Vet Intern Med 2007;21:464-471.
32. Viitmaa R, Cizinauskas S, Bergamasco LA, et al. Magnetic resonance imaging findings in Finnish Spitz dogs with focal epilepsy. J Vet Intern Med 2006;20:305-310.
33. Berg AT, Vickrey BG, Testa FM, et al. How long does it take for epilepsy to become intractable? A prospective investigation. Ann Neurol 2006;60:73-79.
34. Picot MC, Baldy-Moulinier M, Daures JP, et al. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: A population-based study in a Western European country. Epilepsia 2008;49:1230-1238.
35. Jambroszyk M, Tipold A, Potschka H. Add-on treatment with verapamil in pharmacoresistant canine epilepsy. Epilepsia 2011;52:284-291.
36. Von Klopmann T, Rambeck B, Tipold A. Prospective study of zonisamide therapy for refractory idiopathic epilepsy in dogs. J Small Anim Pract 2007;48:134-138.
37. Dewey CW, Cerda-Gonzalez S, Levine JM, et al. Pregabalin as an adjunct to phenobarbital, potassium bromide, or a combination of phenobarbital and potassium bromide for treatment of dogs with suspected idiopathic epilepsy. J Am Vet Med Assoc 2009;235:1442-1449.
38. Rieck S, Rundfeldt C, Tipold A. Anticonvulsant activity and tolerance of ELB138 in dogs with epilepsy: A clinical pilot study. Vet J 2006;172:86-95.
39. Handoko KB, Zwart-van Rijkom JE, Visee HF, et al. Drug treatment-related factors of inadequate seizure control. Epilepsy Behav 2008;13:545-548.
40. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-319.
41. Löscher W, Brandt C. High seizure frequency prior to antiepileptic treatment is a predictor of pharmacoresistant epilepsy in a rat model of temporal lobe epilepsy. Epilepsia 2010;51:89-97.
42. Volk HA, Arabadzisz D, Fritschy JM, et al. Antiepileptic drug-resistant rats differ from drug-responsive rats in hippocampal neurodegeneration and GABA(A) receptor ligand binding in a model of temporal lobe epilepsy. Neurobiol Dis 2006;21:633-646.
43. Volk HA, Loscher W. Multidrug resistance in epilepsy: Rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. Brain 2005;128:1358-1368.
44. Ravizza T, Balosso S, Vezzani A. Inflammation and prevention of epileptogenesis. Neurosci Lett 2011;497:223-230.
45. Gramer I, Leidolf R, Doring B, et al. Breed distribution of the nt230(del4) MDR1 mutation in dogs. Vet J 2011;189:67-71.
46. Alves L, Hulsmeyer V, Jaggy A, et al. Polymorphisms in the ABCB1 gene in phenobarbital responsive and resistant idiopathic epileptic Border Collies. J Vet Intern Med 2011;25:484-489.
47. Tishler DM, Weinberg KI, Hinton DR, et al. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995;36:1-6.
48. West CL, Mealey KL. Assessment of antiepileptic drugs as substrates for canine P-glycoprotein. Am J Vet Res 2007;68:1106-1110.
49. Clark LA, Wahl JM, Rees CA, et al. Retrotransposon insertion in SILV is responsible for merle patterning of the domestic dog. Proc Natl Acad Sci USA 2006;103:1376-1381.